Clinical Trials Logo

Unresectable Cholangiocarcinoma clinical trials

View clinical trials related to Unresectable Cholangiocarcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04088188 Terminated - Clinical trials for Advanced Cholangiocarcinoma

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Start date: January 25, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic). Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and cisplatin with ivosidenib or pemigatinib may work better in treating patients with cholangiocarcinoma compared to gemcitabine and cisplatin alone.